Kairos Pharma Ltd

This management proposal asks stockholders to authorize an amendment to the Certificate of Incorporation granting the Board discretionary authority to implement one or more reverse stock splits at ratios between 1:3 and 1:250. Management frames the change as a tool to increase the per‑share trading price, potentially improving marketability, attracting institutional interest, and reducing transactional frictions associated with low‑priced stock. The Board retains unilateral discretion whether, when, and at which ratio to effect any split even if stockholders approve the amendment, meaning approval provides flexibility but not an obligation to act. The proposal includes a rounding policy for fractional shares (round up) and contemplates equitable adjustments to outstanding awards and authorized plan shares to preserve economic value. The company warns that a reverse split may not produce a sustained price improvement, may reduce share liquidity by reducing the float, could create odd‑lot holdings, and might reduce market capitalization if the market reacts negatively. The Board justifies the broad ratio range to preserve tactical flexibility across differing market conditions and to ensure compliance with NYSE American listing standards at the time of any implementation. From a governance perspective, granting the Board post‑approval discretion concentrates execution authority with management, which can be efficient but raises monitoring considerations for shareholders if a materially dilutive or value‑reducing split were chosen. Overall, the proposal is a routine capital structure amendment used by many small public companies to manage listing and trading dynamics; its benefits depend heavily on market reaction and the Board’s subsequent judgment in selecting whether and how to implement any split.

This advisory proposal asks shareholders to cast a non‑binding 'say‑on‑pay' vote approving the disclosure and structure of named executive officer compensation as presented in the proxy. Management frames compensation objectives around recruitment, retention and alignment of executive incentives with long‑term shareholder value, emphasizing base salaries, RSU grants with multi‑year vesting, and limited perquisites; the company highlights compensation committee oversight and measures intended to avoid problematic practices (no repricing of options without stockholder approval, clawback policy). Because the vote is advisory, it does not legally bind the Board, but the compensation committee commits to consider voting results when making future decisions. For an analyst, key considerations include the quantum and mix of pay (notably sizeable RSU grants and an expanding equity plan), severance/change‑in‑control provisions, and whether pay outcomes are commensurate with performance and company stage. Given the company’s status as an emerging growth company with recent IPO in 2024 and an aggressive equity‑based retention program, investors may weigh potential dilution and alignment tradeoffs. The Board’s recommendation 'FOR' indicates confidence in current design, but investors will evaluate vote results as a governance signal and a feedback mechanism that could prompt adjustments to compensation design or disclosure.

This management proposal seeks shareholder approval to materially expand the equity reserve under the 2023 Equity Incentive Plan by adding 5,000,000 shares and to adopt a ten‑year evergreen that automatically increases the plan reserve by 5% of outstanding shares annually. Management justifies the request as necessary to continue using equity as a primary compensation and retention tool without materially increasing cash payroll expense, arguing the current reserve is insufficient for anticipated grants. From a governance and dilution perspective, the requested increase is large relative to current outstanding shares (21.4 million as of the record date) and the existing reserve (1.65 million), implying meaningful potential dilution if fully utilized; analysts should model potential share count impacts under plausible grant schedules. The evergreen feature automates future increases, reducing recurring administrative and solicitation costs but also diminishing direct shareholder oversight of future dilution; the Board retains discretion to reduce or suspend the annual increase in a given year. The amendment is framed to satisfy NYSE American plan‑approval requirements and to enable certain options to qualify as ISOs under Section 422. Investors will want to evaluate historical grant pacing, CEO and executive equity holdings, burn rate, and governance protections (e.g., repricing restrictions, committee oversight, and performance‑based vesting) to judge appropriateness. The Board’s recommendation 'FOR' signals belief that expanded capacity is needed to attract and retain talent during scale‑up, but the scale and automation of the increase warrant scrutiny by stockholders concerned about dilution and alignment of long‑term incentives.